The primary therapeutic focus of this product is supportive management of dual male sexual dysfunctions, which may help provide symptomatic relief across two core areas. This therapeutic approach addresses the management of dual dysfunction.

Dual Support for Concomitant Erectile and Ejaculatory Issues

This medication is commonly used for adult males experiencing the clinical situation of having Erectile Dysfunction (ED) and Premature Ejaculation (PE). It assists with managing symptom clusters that may create noticeable physiological strain, applied across therapeutic domains where additional symptomatic support is needed. It is considered relevant for easing symptoms related to insufficient penile rigidity and inadequate control over ejaculation.

In clinical scenarios, the combination approach is relevant in situations requiring additional management of discomfort, helping ease the overall symptom burden. This approach is applied across domains where short-term symptom management is appropriate, and may assist with managing symptoms that create noticeable physiological strain.

Quick Fact: Support for Dual Dysfunction Symptoms This medication is used to help with symptomatic support for concurrent conditions involving erection insufficiency and ejaculatory control issues, supports patients during episodes of heightened discomfort.

Official Eligibility Profile

The use of Vigora is strictly governed by population eligibility rules derived from the regulatory labeling of its components (Dapoxetine and Sildenafil). Eligibility is strictly confined to adult men and is defined by a series of absolute prohibitions and conditional restrictions.

Who Can and Cannot Use Vigora

Eligibility Status	Description based on Official Regulatory Labeling
Allowed	Adult Males aged 18 to 64 years who meet all specific diagnostic criteria.
Contraindicated	Patients using organic nitrates or guanylate cyclase stimulators (e.g., riociguat).
	Individuals with a history of vision loss due to NAION or known hypersensitivity to the ingredients.

Key Population Restrictions

The medicine is contraindicated for patients with specific health histories, including severe depression, bipolar disorder, a history of syncope, or significant pathological cardiac conditions (such as severe heart failure or recent stroke/myocardial infarction). It is also contraindicated in patients with moderate or severe hepatic impairment.

Age Restrictions preclude the pediatric population (under 18 years) from use. The medicine is not indicated for women. Use is not recommended for the geriatric population (aged 65 and over) or for patients with severe renal impairment due to safety and efficacy not being fully established in these groups. Use requires caution in patients with resting hypotension or conditions that predispose to priapism (e.g., sickle cell anaemia).

Interactions with other medicines and products

Vigora (sildenafil) interacts with several medication classes, primarily through pharmacodynamic effects and altered drug metabolism.

Contraindicated Combinations

The co-administration of sildenafil with organic nitrates or nitric oxide donors (e.g., nitroglycerin) is strictly contraindicated due to the risk of severe, life-threatening hypotension. Similarly, combination with guanylate cyclase (GC) stimulators, such as riociguat, is forbidden.

Clinically Significant Interactions

Interacting Substance/Class	Mechanism & Effect	Official Requirement
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole)	Reduce sildenafil clearance, significantly increasing plasma exposure (AUC).	Dose limitation or adjustment is required.
Alpha-blockers	Additive vasodilatory effect, increasing the risk of symptomatic hypotension.	Initiation should occur only after the patient is hemodynamically stable on the alpha-blocker.
High-Fat Meal	Reduces the rate of absorption of sildenafil.	Delays the time to peak concentration (T max).

Timing and Population Considerations

The most stringent timing constraint is for Ritonavir, where the maximum single dose of sildenafil must not exceed 25 mg within a 48-hour period. Patients with hepatic impairment (e.g., severe liver disease) require careful management due to reduced drug clearance, which increases sildenafil exposure.

Targeting the PDE5 Enzyme and cGMP Signaling

The drug functions as a selective inhibitor of the Phosphodiesterase type 5 (PDE5) enzyme, which is responsible for breaking down the cellular messenger cyclic Guanosine Monophosphate (cGMP). By blocking this enzyme, the drug leads to a buildup of cGMP in specific vascular smooth muscle cells, thus increasing the concentration of the signaling molecule cGMP within the tissue.

Relaxation of Vascular Smooth Muscle

The elevated levels of cGMP initiate a downstream molecular cascade that causes the smooth muscle lining local blood vessels to relax. This action results in vasodilation, which is the widening of the vessels, and results in increased localized blood flow. This physiological change is the consequence of the drug's targeted mechanism.

The administration of the Vigora product is defined by a dual-component system, requiring the use of both the oral tablet (containing Sildenafil and Dapoxetine) and the topical spray (containing Lidocaine). The regimen is strictly intermittent (as-needed), tied directly to anticipated sexual activity.

Official Dosing and Frequency

The maximum frequency for administering the oral tablet is once per day (once every 24 hours), which is a key principle across the systemic components. The Sildenafil component typically starts at a 50 mg dose, with label-specified adjustments permissible down to 25 mg or up to a maximum of 100 mg. The Dapoxetine component generally begins at 30 mg, with a maximum recommended dose of 60 mg.

Administration Conditions

Administration of the oral tablet should occur approximately one hour before activity, although guidelines allow for intake between 30 minutes and four hours prior to the event. The tablet may be taken with or without food, but ingestion with a high-fat meal may lead to a delay in the onset of action. The tablet must be swallowed whole with at least one full glass of water. The topical component requires a brief absorption time, and any residual spray must be removed before sexual activity to adhere to procedural guidelines.

Population-Specific Use

Use of the oral components is not indicated for individuals under the age of 18. Dose reduction is a standard consideration for certain groups; for example, a reduced Sildenafil starting dose of 25 mg is typically considered for older adults (65 years and over) or those with severe renal or hepatic impairment.

Research Evidence / Overview of Studies for Vigora

Evidence from Randomized Controlled Trials (RCTs) for Dual Dysfunction

The core research involves short-term Randomized Controlled Trials (RCTs). The systemic components of Vigora (Dapoxetine and Sildenafil) was evaluated in adult males presenting with co-existing Erectile Dysfunction (ED) and Premature Ejaculation (PE). These studies examined how measured outcomes related to erection maintenance and ejaculatory control changed over defined time intervals.

In these studies, researchers measured objective outcomes like the Intravaginal Ejaculatory Latency Time (IELT), which is the stopwatch-measured time to ejaculation. They also monitored patient-reported outcomes describing perceived discomfort and overall satisfaction, using validated questionnaires. Research describes patterns observed in the studies where participants receiving the combination therapy had measured shifts in both ejaculatory latency and functional erectile scores, compared to baseline.

Research on Combination vs. Single-Agent Therapies

The research landscape also includes studies that explored the use of the combination therapy against using Sildenafil or Dapoxetine as single-agent treatments. The aim of this research was to explore functional scores and patient-reported outcomes describing perceived discomfort when the two systemic agents are used together versus separately.

These comparative studies described patterns where the combined approach was associated with different measurement results for both the measured ejaculatory time and the scores related to erection maintenance, compared to the single agents. These data show patterns related to the outcomes related to systemic or functional imbalance monitored in trials, but findings describe group patterns, not personal outcomes.

Research Gaps and Areas of Uncertainty

Research regarding the fixed-dose three-component product, which includes the topical component Lidocaine, presents a distinct research scenario. The evidence is limited and is not characterized by the same volume of large-scale RCTs as the dual systemic combination. The certainty remains low for drawing direct, broad conclusions based on official regulatory data about the fixed-dose three-component combination, as the comparative evidence is lacking for the precise effects of all three agents together.

Furthermore, the follow-up durations were limited in most of the pivotal clinical trials. Research primarily explored short-term symptom changes over periods of 4 to 12 weeks. Therefore, the long-term effects are not fully established, and there is limited information for long-term outcomes related to the sustained consistency of the measured outcomes monitored.

Common questions about Vigora (FAQ)

---

Q: How long do the effects of Vigora typically last?

Official information indicates that the therapeutic effect of the Sildenafil component is generally sustained for approximately 3 to 5 hours. This estimate is based on the drug's terminal half-life in the body. The Dapoxetine component, which affects ejaculatory control, has a shorter initial half-life of about 1 to 2 hours.

---

Q: What should I do if I miss a dose of Vigora?

According to the official product information, this medicine is intended for use only as needed before anticipated activity. It is not designed to be taken on a regular schedule. Therefore, the concept of a "missed dose" does not apply, and it should only be taken when planned.

---

Q: Does Vigora interact with common over-the-counter pain relievers?

Regulatory documents for the Dapoxetine component note potential interactions with non-steroidal anti-inflammatory medicines (NSAIDs). This class of over-the-counter pain relievers includes medicines like ibuprofen and acetylsalicylic acid. Information regarding specific drug interactions can be found in the full official labeling.

---

Q: Can Vigora be taken with alcohol?

Official guidance from regulatory documents advises avoiding the consumption of alcohol when taking this medication. Alcohol can increase the central nervous system effects of the Dapoxetine component, which may intensify symptoms such as dizziness, sleepiness, or slow reactions.

---

Q: Does taking Vigora affect fertility?

Studies examining the effects of the Sildenafil component in non-clinical settings did not find that it affected the motility or morphology of sperm. The drug is approved strictly for use in adult men and is not indicated for women or for use in fertility treatments.

---

Q: Does Vigora lose its effectiveness over time if used regularly?

Evidence from long-term, open-label studies of the Sildenafil component suggests that the effectiveness was generally maintained over the study period for the majority of participants. This research followed individuals for up to four years to monitor the consistency of outcomes.

---

Q: How long after stopping Vigora does it completely leave the body?

Based on the Sildenafil component's terminal half-life of 3 to 5 hours, the drug is typically cleared from the plasma within about 24 hours. Drug elimination is a gradual process dependent on the body's metabolism and is described in the official pharmacokinetic information.

---

Q: Can Vigora be taken by people who have high blood pressure?

Official eligibility documents advise that the medicine is contraindicated for patients with significant pathological cardiac conditions. Furthermore, it is not recommended for individuals for whom sexual activity is medically inadvisable due to cardiovascular risk. Caution is generally advised for those with certain pre-existing cardiovascular risks, including some forms of high blood pressure.

---

Q: Are there any common foods that should be avoided when taking Vigora?

The official labeling advises that consuming a high-fat meal can delay the rate at which the medication is absorbed, which in turn delays its onset of action. Additionally, regulatory information indicates that consuming grapefruit and grapefruit juice should be avoided because they can potentially increase the concentration of the Sildenafil component in the body.

---

Q: Does taking Vigora require prior stimulation to work?

Yes, according to the official product information, the Sildenafil component requires sexual stimulation to be effective. The medicine does not directly cause an erection; rather, it works by enhancing the natural physiological response to nitric oxide that is released during stimulation.

---

Q: What happens if I take Vigora too close to another dose?

Official dosing instructions restrict the use of the oral tablet to a maximum of once per day (24 hours). Taking the medication more frequently than this can increase the risk of experiencing common side effects, such as headache, flushing, dizziness, and changes in vision, as described in the official safety profile.

---

Q: Why is Vigora sometimes associated with a blue-tinted vision?

The transient color tinge, sometimes described as a blue-tinted vision, is a documented side effect related to the Sildenafil component. This effect is caused by a minor inhibitory action on the phosphodiesterase type 6 (PDE6) enzyme, a substance naturally present in the photoreceptor cells of the retina.

---

Q: Is Vigora a treatment for the underlying cause of erectile dysfunction?

The official therapeutic purpose of the medicine is the treatment of the symptoms associated with erectile dysfunction and premature ejaculation. The drug does not alter or treat the fundamental medical causes of these conditions, and its effect is temporary, lasting only as long as the medicine is active in the body.

---

Q: Why is Vigora not allowed for people taking guanylate cyclase stimulators?

This combination is strictly forbidden because both the Sildenafil component and guanylate cyclase stimulators increase the level of a signaling molecule called cyclic Guanosine Monophosphate (cGMP). This overlapping action can result in a dangerous, severe reduction in blood pressure, known as hypotension, as stated in the official safety information.

The storage and disposal of this combination medicine, which includes oral tablets and a topical spray, must adhere to the specific requirements detailed in official regulatory labeling to ensure stability and public safety.

Storage Conditions

The tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and protected from both excessive moisture and light [Source: Regulatory SmPC/FDA principles]. The product must be kept in its original container and stored out of the sight and reach of children [Source: NIH MedlinePlus/FDA].

Special Handling: Both the tablets and the pressurized spray container must not be frozen. The topical spray container is subject to mandatory warnings: it must not be punctured, burned, or exposed to high heat [Source: Regulatory Aerosol Warnings].

Disposal Instructions

Any unused or expired product must be disposed of according to local regulations [Source: EMA/FDA/Local Authority Guidance]. Regulators typically recommend utilizing a drug take-back program or authorized collector to dispose of the medication safely. The medicine should not be flushed down a toilet or sink unless specifically directed by the product's official instructions.